Yüklüyor......

EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation

The efficacy of EGFR tyrosine kinase inhibitors (TKIs) varies among different EGFR mutations. Here, we directly compared the efficacy of first-line TKIs to chemotherapy for non-small cell lung cancer (NSCLC) patients with the L858R mutation. The progression-free survival (PFS) for patients receiving...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Sci Rep
Asıl Yazarlar: Xu, Jianlin, Yang, Haitang, Jin, Bo, Lou, Yuqing, Zhang, Yanwei, Zhang, Xueyan, Zhong, Hua, Wang, Huiming, Wu, Dan, Han, Baohui
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group 2016
Konular:
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5095672/
https://ncbi.nlm.nih.gov/pubmed/27811976
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep36371
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!